Ключевые слова
Как цитировать
Аннотация
Выявление мутаций в генах BRCA1/2 стало неотъемлемым компонентом современной онкологии. Многие существенные аспекты, связанные с диагностикой наследственных опухолевых синдромов, в частности, принципы отбора пациентов для BRCA1/2-тестирования, оптимальный объём молекулярно-генетического анализа, характер медицинских мероприятий в отношении выявленных носителей и т.д. могут вызывать затруднения у практикующих онкологов и являются предметом для дискуссии у специалистов лабораторного профиля. Данная работа является итогом обсуждения различных нюансов BRCA1/2-диагностики, в котором участвовали специалисты с многолетним опытом в области генетики рака, и которое проводилось под эгидой Межрегиональной общественной организации молекулярных генетиков в онкологии и онкогематологии.
Библиографические ссылки
Hatano Y, Tamada M, Matsuo M et al. Molecular Trajectory of BRCA1 and BRCA2 Mutations // Front Oncol. 2020;10:361. doi:10.3389/fonc.2020.00361
Royfman R, Whiteley E, Noe O et al. BRCA1/2 signaling and homologous recombination deficiency in breast and ovarian cancer // Future Oncol. 2021;17(21):2817–2830. doi:10.2217/fon-2021-0072
Richards S, Aziz N, Bale S et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology // Genet Med. 2015;17(5):405–24. doi:10.1038/gim.2015.30
Imyanitov EN. Cytotoxic and targeted therapy for BRCA1/2-driven cancers // Hered Cancer Clin Pract. 2021;19(1):36. doi:10.1186/s13053-021-00193-y
Rebbeck TR, Mitra N, Wan F et al. Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer // JAMA. 2015;313(13):1347–61. doi:10.1001/jama.2014.5985
Chaffee KG, Oberg AL, McWilliams RR et al. Prevalence of germline mutations in cancer genes among pancreatic cancer patients with a positive family history // Genet Med. 2018;20(1):119–127. doi:10.1038/gim.2017.85
Nyberg T, Frost D, Barrowdale D et al. Prostate Cancer Risks for Male BRCA1 and BRCA2 Mutation Carriers: A Prospective Cohort Study // Eur Urol. 2020;77(1):24–35. doi:10.1016/j.eururo.2019.08.025
Silvestri V, Leslie G, Barnes DR et al. Characterization of the Cancer Spectrum in Men with Germline BRCA1 and BRCA2 Pathogenic Variants: Results From the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) // JAMA Oncol. 2020;6(8):1218–1230. doi:10.1001/jamaoncol.2020.2134
Sokol ES, Pavlick D, Khiabanian H et al. Pan-Cancer Analysis of BRCA1 and BRCA2 Genomic Alterations and Their Association with Genomic Instability as Measured by Genome-Wide Loss of Heterozygosity // JCO Precis Oncol. 2020;4:442–465. doi:10.1200/po.19.00345
Power R, Leavy C, Nolan C et al. Prevalence of pancreaticobiliary cancers in Irish families with pathogenic BRCA1 and BRCA2 variants // Fam Cancer. 2021;20(2):97–101. doi:10.1007/s10689-020-00205-1
Avanesyan AA, Sokolenko AP, Ivantsov AO et al. Gastric Cancer in BRCA1 Germline Mutation Carriers: Results of Endoscopic Screening and Molecular Analysis of Tumor Tissues // Pathobiology. 2020;87(6):367–374. doi:10.1159/000511323
Maccaroni E, Giampieri R, Lenci E et al. BRCA mutations and gastrointestinal cancers: When to expect the unexpected? // World J Clin Oncol. 2021;12(7):565–580. doi:10.5306/wjco.v12.i7.565
Jonsson P, Bandlamudi C, Cheng ML et al. Tumour lineage shapes BRCA-mediated phenotypes // Nature. 2019;571(7766):576–579. doi:10.1038/s41586-019-1382-1
Stoppa-Lyonnet D. The biological effects and clinical implications of BRCA mutations: where do we go from here? // Eur J Hum Genet. 2016;24(Suppl. 1):S3–9. doi:10.1038/ejhg.2016.93
Brown GR, Simon M, Wentling C et al. A review of inherited cancer susceptibility syndromes // JAAPA. 2020;33(12):10–16. doi:10.1097/01.JAA.0000721648.46099.2c
Boddicker NJ, Hu C, Weitzel JN et al. Risk of Late-Onset Breast Cancer in Genetically Predisposed Women // J Clin Oncol. 2021;39(31):3430–3440. doi:10.1200/JCO.21.00531
Toss A, Molinaro E, Venturelli M et al. BRCA Detection Rate in an Italian Cohort of Luminal Early-Onset and Triple-Negative Breast Cancer Patients without Family History: When Biology Overcomes Genealogy // Cancers (Basel). 2020;12(5):1252. doi:10.3390/cancers12051252
Artioli G, Giannone G, Valabrega G et al. Characteristics and outcome of BRCA mutated epithelial ovarian cancer patients in Italy: A retrospective multicenter study (MITO 21) // Gynecol Oncol. 2021;161(3):755–761. doi:10.1016/j.ygyno.2021.04.014
Sokolenko AP, Sokolova TN, Ni VI et al. Frequency and spectrum of founder and non-founder BRCA1 and BRCA2 mutations in a large series of Russian breast cancer and ovarian cancer patients // Breast Cancer Res Treat. 2020;184(1):229–235. doi:10.1007/s10549-020-05827-8
Breast Cancer Association Consortium, Dorling L, Carvalho S et al. Breast Cancer Risk Genes — Association Analysis in More than 113,000 Women // N Engl J Med. 2021;384(5):428–439. doi:10.1056/NEJMoa1913948
Hu C, Hart SN, Gnanaolivu R et al. A Population-Based Study of Genes Previously Implicated in Breast Cancer // N Engl J Med. 2021;384(5):440–451. doi:10.1056/NEJMoa2005936
Alsop K, Fereday S, Meldrum C et al. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group // J Clin Oncol. 2012;30(21):2654–63. doi:10.1200/JCO.2011.39.8545
Gorodnova T, Sokolenko A, Ni V et al. BRCA1-associated and sporadic ovarian carcinomas: outcomes of primary cytoreductive surgery or neoadjuvant chemotherapy // Int J Gynecol Cancer. 2019;29(4):779–786. doi:10.1136/ijgc-2018-000175
Gallagher DJ, Gaudet MM, Pal P et al. Germline BRCA mutations denote a clinicopathologic subset of prostate cancer // Clin Cancer Res. 2010;16(7):2115–21. doi:10.1158/1078-0432.CCR-09-2871
Darst BF, Dadaev T, Saunders E et al. Germline Sequencing DNA Repair Genes in 5545 Men with Aggressive and Nonaggressive Prostate Cancer // J Natl Cancer Inst. 2021;113(5):616–625. doi:10.1093/jnci/djaa132
Mersch J, Jackson MA, Park M et al. Cancers associated with BRCA1 and BRCA2 mutations other than breast and ovarian // Cancer. 2015;121(2):269–75. doi:10.1002/cncr.29041
Shindo K, Yu J, Suenaga M et al. Deleterious Germline Mutations in Patients with Apparently Sporadic Pancreatic Adenocarcinoma // J Clin Oncol. 2017;35(30):3382–3390. doi:10.1200/JCO.2017.72.3502
Fountzilas E, Eliades A, Koliou GA et al. Clinical Significance of Germline Cancer Predisposing Variants in Unselected Patients with Pancreatic Adenocarcinoma // Cancers (Basel). 2021;13(2):198. doi:10.3390/cancers13020198
van den Broek AJ, de Ruiter K, van 't Veer LJ et al. Evaluation of the Dutch BRCA1/2 clinical genetic center referral criteria in an unselected early breast cancer population // Eur J Hum Genet. 2015;23(5):588–95. doi:10.1038/ejhg.2014.161
Engel C, Rhiem K, Hahnen E et al Prevalence of pathogenic BRCA1/2 germline mutations among 802 women with unilateral triple-negative breast cancer without family cancer history // BMC Cancer. 2018;18(1):265. doi:10.1186/s12885-018-4029-y
Pujol P, Barberis M, Beer P et al. Clinical practice guidelines for BRCA1 and BRCA2 genetic testing // Eur J Cancer. 2021;146:30–47. doi:10.1016/j.ejca.2020.12.023
Maxwell KN, Wubbenhorst B, Wenz BM et al. BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriers // Nat Commun. 2017;8(1):319. doi:10.1038/s41467-017-00388-9
Paluch-Shimon S, Cardoso F, Sessa C et al. Prevention and screening in BRCA mutation carriers and other breast/ovarian hereditary cancer syndromes: ESMO Clinical Practice Guidelines for cancer prevention and screening // Ann Oncol. 2016;27(suppl. 5):v103–v110. doi:10.1093/annonc/mdw327
Daly MB, Pal T, Berry MP et al. Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology // J Natl Compr Canc Netw. 2021;19(1):77–102. doi:10.6004/jnccn.2021.0001
Collins JM, Isaacs C. Management of breast cancer risk in BRCA1/2 mutation carriers who are unaffected with cancer // Breast J. 2020;26(8):1520–1527. doi:10.1111/tbj.13970
Walker M, Jacobson M, Sobel M. Management of ovarian cancer risk in women with BRCA1/2 pathogenic variants // CMAJ. 2019;191(32):E886–E893. doi:10.1503/cmaj.190281
Carroll PR, Parsons JK, Andriole G et al. NCCN Guidelines Insights: Prostate Cancer Early Detection, Version 2.2016 // J Natl Compr Canc Netw. 2016;14(5):509–19. doi:10.6004/jnccn.2016.0060
Dullens B, de Putter R, Lambertini M et al. Cancer Surveillance in Healthy Carriers of Germline Pathogenic Variants in BRCA1/2: A Review of Secondary Prevention Guidelines // J Oncol. 2020;2020:9873954. doi:10.1155/2020/9873954
Rebbeck TR, Kauff ND, Domchek SM. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers // J Natl Cancer Inst. 2009;101(2):80–7. doi:10.1093/jnci/djn442
Ludwig KK, Neuner J, Butler A et al. Risk reduction and survival benefit of prophylactic surgery in BRCA mutation carriers, a systematic review // Am J Surg. 2016;212(4):660–669. doi:10.1016/j.amjsurg.2016.06.010
Это произведение доступно по лицензии Creative Commons «Attribution-NonCommercial-NoDerivatives» («Атрибуция — Некоммерческое использование — Без производных произведений») 4.0 Всемирная.
© АННМО «Вопросы онкологии», Copyright (c) 2022